{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:58:23Z","timestamp":1790621903472,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,1,25]],"date-time":"2017-01-25T00:00:00Z","timestamp":1485302400000},"content-version":"vor","delay-in-days":390,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Nucleic Acids"],"published-print":{"date-parts":[[2016]]},"DOI":"10.1038\/mtna.2016.87","type":"journal-article","created":{"date-parts":[[2016,10,18]],"date-time":"2016-10-18T11:28:07Z","timestamp":1476790087000},"page":"e379","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"special_numbering":"C","title":["Antisense Oligonucleotide-mediated Exon Skipping as a Systemic Therapeutic Approach for Recessive Dystrophic Epidermolysis Bullosa"],"prefix":"10.1016","volume":"5","author":[{"given":"Jeroen","family":"Bremer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bornert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Nystr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Gostynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel F","family":"Jonkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemieke","family":"Aartsma-Rus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C","family":"van den Akker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna MG","family":"Pasmooij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/mtna.2016.87_bib1","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.jaad.2014.01.903","article-title":"Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification","volume":"70","author":"Fine","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1038\/mtna.2016.87_bib2","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1083\/jcb.103.4.1577","article-title":"Type VII collagen is a major structural component of anchoring fibrils","volume":"103","author":"Sakai","year":"1986","journal-title":"J Cell Biol"},{"key":"10.1038\/mtna.2016.87_bib3","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jaad.2009.03.052","article-title":"Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part I. Epithelial associated tissues","volume":"61","author":"Fine","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1038\/mtna.2016.87_bib4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jaad.2008.09.035","article-title":"Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986-2006","volume":"60","author":"Fine","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1038\/mtna.2016.87_bib5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1749-6632.1985.tb51156.x","article-title":"The structure of type VII collagen","volume":"460","author":"Burgeson","year":"1985","journal-title":"Ann N Y Acad Sci"},{"key":"10.1038\/mtna.2016.87_bib6","doi-asserted-by":"crossref","first-page":"21649","DOI":"10.1074\/jbc.M100180200","article-title":"The carboxyl terminus of type VII collagen mediates antiparallel dimer formation and constitutes a new antigenic epitope for epidermolysis Bullosa acquisita autoantibodies","volume":"276","author":"Chen","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1038\/mtna.2016.87_bib7","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1172\/JCI34292","article-title":"A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy","volume":"118","author":"Fritsch","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1038\/mtna.2016.87_bib8","doi-asserted-by":"crossref","first-page":"264ra165","DOI":"10.1126\/scitranslmed.3010083","article-title":"Genetically corrected iPSCs as cell therapy for recessive dystrophic epidermolysis bullosa","volume":"6","author":"Wenzel","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1038\/mtna.2016.87_bib9","doi-asserted-by":"crossref","first-page":"264ra163","DOI":"10.1126\/scitranslmed.3009540","article-title":"Human COL7A1-corrected induced pluripotent stem cells for the treatment of recessive dystrophic epidermolysis bullosa","volume":"6","author":"Sebastiano","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1038\/mtna.2016.87_bib10","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/jid.2013.523","article-title":"Patient-specific naturally gene-reverted induced pluripotent stem cells in recessive dystrophic epidermolysis bullosa","volume":"134","author":"Tolar","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1038\/mtna.2016.87_bib11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/mt.2008.234","article-title":"Injection of recombinant human type VII collagen corrects the disease phenotype in a murine model of dystrophic epidermolysis bullosa","volume":"17","author":"Remington","year":"2009","journal-title":"Mol Ther"},{"key":"10.1038\/mtna.2016.87_bib12","doi-asserted-by":"crossref","first-page":"e307","DOI":"10.1038\/mtna.2016.19","article-title":"Gene editing for the efficient correction of a recurrent COL7A1 mutation in recessive dystrophic epidermolysis bullosa keratinocytes","volume":"5","author":"Chamorro","year":"2016","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1038\/mtna.2016.87_bib13","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/oli.2009.0215","article-title":"Exonic sequences provide better targets for antisense oligonucleotides than splice site sequences in the modulation of Duchenne muscular dystrophy splicing","volume":"20","author":"Aartsma-Rus","year":"2010","journal-title":"Oligonucleotides"},{"key":"10.1038\/mtna.2016.87_bib14","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/bjd.13945","article-title":"A COL7A1 variant leading to in-frame skipping of exon 15 attenuates disease severity in recessive dystrophic epidermolysis bullosa","volume":"173","author":"Schwieger-Briel","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1038\/mtna.2016.87_bib15","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/bjd.13386","article-title":"Skipped exon in COL7A1 determines the clinical phenotypes of dystrophic epidermolysis bullosa","volume":"172","author":"Toyonaga","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1038\/mtna.2016.87_bib16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jdermsci.2009.06.015","article-title":"Long-term follow-up of patients with recessive dystrophic epidermolysis bullosa in the Netherlands: expansion of the mutation database and unusual phenotype-genotype correlations","volume":"56","author":"van den Akker","year":"2009","journal-title":"J Dermatol Sci"},{"key":"10.1038\/mtna.2016.87_bib17","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/978-1-61779-767-5_15","article-title":"Antisense-mediated exon skipping to reframe transcripts","volume":"867","author":"Turczynski","year":"2012","journal-title":"Methods Mol Biol"},{"key":"10.1038\/mtna.2016.87_bib18","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1038\/sj.jid.5700435","article-title":"Targeted skipping of a single exon harboring a premature termination codon mutation: implications and potential for gene correction therapy for selective dystrophic epidermolysis bullosa patients","volume":"126","author":"Goto","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1038\/mtna.2016.87_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/mt.2016.92","article-title":"Functional evaluation of targeted exon deletion reveals prospect for dystrophic epidermolysis bullosa therapy","author":"Bornert","year":"2016","journal-title":"Mol Ther"},{"key":"10.1038\/mtna.2016.87_bib20","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1093\/nar\/gkp215","article-title":"Human Splicing Finder: an online bioinformatics tool to predict splicing signals","volume":"37","author":"Desmet","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"10.1038\/mtna.2016.87_bib21","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1046\/j.1523-1747.2000.00938.x","article-title":"Spontaneous cell sorting of fibroblasts and keratinocytes creates an organotypic human skin equivalent","volume":"114","author":"Wang","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1038\/mtna.2016.87_bib22","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/mt.2010.72","article-title":"Preclinical PK and PD studies on 2'-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model","volume":"18","author":"Heemskerk","year":"2010","journal-title":"Mol Ther"},{"key":"10.1038\/mtna.2016.87_bib23","article-title":"RNA-based therapies for genodermatoses","author":"Bornert","year":"2016","journal-title":"Exp Dermatol"},{"key":"10.1038\/mtna.2016.87_bib24","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jid.2015.10.050","article-title":"Progress toward Treatment and Cure of Epidermolysis Bullosa: Summary of the DEBRA International Research Symposium EB2015","volume":"136","author":"Uitto","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1038\/mtna.2016.87_bib25","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1038\/jid.2008.78","article-title":"Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa","volume":"128","author":"Wong","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1038\/mtna.2016.87_bib26","doi-asserted-by":"crossref","first-page":"264ra164","DOI":"10.1126\/scitranslmed.3009342","article-title":"Induced pluripotent stem cells from human revertant keratinocytes for the treatment of epidermolysis bullosa","volume":"6","author":"Umegaki-Arao","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1038\/mtna.2016.87_bib27","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0140-6736(13)61897-8","article-title":"Allogeneic blood and bone marrow cells for the treatment of severe epidermolysis bullosa: repair of the extracellular matrix","volume":"382","author":"Tolar","year":"2013","journal-title":"Lancet"},{"key":"10.1038\/mtna.2016.87_bib28","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/978-1-61779-767-5_6","article-title":"Overview on applications of antisense-mediated exon skipping","volume":"867","author":"van Roon-Mom","year":"2012","journal-title":"Methods Mol Biol"},{"key":"10.1038\/mtna.2016.87_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2016.07.029","article-title":"Targeted exon skipping restores type VII collagen expression and anchoring fibril formation in an in vivo RDEB model","author":"Turczynski","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1038\/mtna.2016.87_bib30","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/1523-1747.ep12364899","article-title":"Intracytoplasmic retention of type VII collagen and dominant dystrophic epidermolysis bullosa: reversal of defect following cessation of or marked improvement in disease activity","volume":"101","author":"Fine","year":"1993","journal-title":"J Invest Dermatol"},{"key":"10.1038\/mtna.2016.87_bib31","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/mt.2009.144","article-title":"Mechanisms of fibroblast cell therapy for dystrophic epidermolysis bullosa: high stability of collagen VII favors long-term skin integrity","volume":"17","author":"Kern","year":"2009","journal-title":"Mol Ther"},{"key":"10.1038\/mtna.2016.87_bib32","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1002\/humu.21551","article-title":"The international dystrophic epidermolysis bullosa patient registry: an online database of dystrophic epidermolysis bullosa patients and their COL7A1 mutations","volume":"32","author":"van den Akker","year":"2011","journal-title":"Hum Mutat"},{"key":"10.1038\/mtna.2016.87_bib33","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1600-0625.2008.00723.x","article-title":"Mutation analysis and characterization of COL7A1 mutations in dystrophic epidermolysis bullosa","volume":"17","author":"Dang","year":"2008","journal-title":"Exp Dermatol"},{"key":"10.1038\/mtna.2016.87_bib34","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/humu.21651","article-title":"The COL7A1 mutation database","volume":"33","author":"Wertheim-Tysarowska","year":"2012","journal-title":"Hum Mutat"},{"key":"10.1038\/mtna.2016.87_bib35","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1089\/hum.2014.086","article-title":"Translational and regulatory challenges for exon skipping therapies","volume":"25","author":"Aartsma-Rus","year":"2014","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mtna.2016.87_bib36","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1011367","article-title":"Systemic administration of PRO051 in Duchenne's muscular dystrophy","volume":"364","author":"Goemans","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1038\/mtna.2016.87_bib37","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.nmd.2013.06.369","article-title":"194th ENMC international workshop. 3rd ENMC workshop on exon skipping: towards clinical application of antisense-mediated exon skipping for Duchenne muscular dystrophy 8-10 December 2012, Naarden, The Netherlands","volume":"23","author":"Aartsma-Rus","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"10.1038\/mtna.2016.87_bib38","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S1474-4422(14)70195-4","article-title":"Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study","volume":"13","author":"Voit","year":"2014","journal-title":"Lancet Neurol"}],"container-title":["Molecular Therapy - Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253117301063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253117301063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T01:27:03Z","timestamp":1761874023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253117301063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":38,"alternative-id":["S2162253117301063"],"URL":"https:\/\/doi.org\/10.1038\/mtna.2016.87","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antisense Oligonucleotide-mediated Exon Skipping as a Systemic Therapeutic Approach for Recessive Dystrophic Epidermolysis Bullosa","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/mtna.2016.87","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Official journal of the American Society of Gene & Cell Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"e379"}}